122 related articles for article (PubMed ID: 38018328)
1. Excellent hepatitis C virus cure rates despite increasing complexity of people who use drugs: Integrated-Test-stage Treat study final outcomes.
O'Sullivan M; Jones AM; Mourad A; Haddadin Y; Verma S
J Viral Hepat; 2024 Feb; 31(2):66-77. PubMed ID: 38018328
[TBL] [Abstract][Full Text] [Related]
2. ITTREAT (Integrated Community Test - Stage - TREAT) Hepatitis C service for people who use drugs: Real-world outcomes.
O'Sullivan M; Jones AM; Gage H; Jordan J; MacPepple E; Williams H; Verma S
Liver Int; 2020 May; 40(5):1021-1031. PubMed ID: 32048798
[TBL] [Abstract][Full Text] [Related]
3. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.
Macías J; Morano LE; Téllez F; Granados R; Rivero-Juárez A; Palacios R; Ríos M; Merino D; Pérez-Pérez M; Collado A; Figueruela B; Morano A; Freyre-Carrillo C; Martín JM; Rivero A; García F; Pineda JA;
J Hepatol; 2019 Jul; 71(1):45-51. PubMed ID: 30853642
[TBL] [Abstract][Full Text] [Related]
4. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.
Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Janjua NZ; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J
J Hepatol; 2020 Apr; 72(4):643-657. PubMed ID: 31785345
[TBL] [Abstract][Full Text] [Related]
6. Direct-acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment.
Scherz N; Bruggmann P; Brunner N
Int J Drug Policy; 2018 Dec; 62():74-77. PubMed ID: 30368101
[TBL] [Abstract][Full Text] [Related]
7. Direct-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, Canada.
Selfridge M; Cunningham EB; Milne R; Drost A; Barnett T; Lundgren K; Guarasci K; Grebely J; Fraser C
Int J Drug Policy; 2019 Oct; 72():106-113. PubMed ID: 31178254
[TBL] [Abstract][Full Text] [Related]
8. Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy.
Akiyama MJ; Lipsey D; Heo M; Agyemang L; Norton BL; Hidalgo J; Lora K; Litwin AH
Clin Infect Dis; 2020 Jun; 70(12):2695-2702. PubMed ID: 31346609
[TBL] [Abstract][Full Text] [Related]
9. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic.
Norton BL; Fleming J; Bachhuber MA; Steinman M; DeLuca J; Cunningham CO; Johnson N; Laraque F; Litwin AH
Int J Drug Policy; 2017 Sep; 47():196-201. PubMed ID: 28811158
[TBL] [Abstract][Full Text] [Related]
10. High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study.
Yee J; Carson JM; Hajarizadeh B; Hanson J; O'Beirne J; Iser D; Read P; Balcomb A; Doyle JS; Davies J; Martinello M; Marks P; Dore GJ; Matthews GV;
Hepatol Commun; 2022 Mar; 6(3):496-512. PubMed ID: 34729957
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Current Opioid Agonist Therapy on Hepatitis C Virus Treatment Initiation Among People Who Use Drugs From the Direct-acting Antiviral (DAA) Era: A Population-Based Study.
Bartlett SR; Wong S; Yu A; Pearce M; MacIsaac J; Nouch S; Adu P; Wilton J; Samji H; Clementi E; Velasquez H; Jeong D; Binka M; Alvarez M; Wong J; Buxton J; Krajden M; Janjua NZ
Clin Infect Dis; 2022 Mar; 74(4):575-583. PubMed ID: 34125883
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with lost to follow-up after hepatitis C treatment delivered by primary care teams in an inner-city multi-site program, Vancouver, Canada.
Nouch S; Gallagher L; Erickson M; Elbaharia R; Zhang W; Wang L; Bacani N; Kason D; Kleban H; Knebel L; Hall D; Barrios R; Hull M
Int J Drug Policy; 2018 Sep; 59():76-84. PubMed ID: 30048877
[TBL] [Abstract][Full Text] [Related]
13. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
[TBL] [Abstract][Full Text] [Related]
14. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
[TBL] [Abstract][Full Text] [Related]
15. Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada.
Selfridge M; Cunningham EB; Barnett T; Drost A; Gray-Schleihauf C; Guarasci K; Lundgren K; Milne R; Grebely J; Fraser C
Int J Drug Policy; 2021 Oct; 96():103418. PubMed ID: 34538704
[TBL] [Abstract][Full Text] [Related]
16. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017.
Aas CF; Vold JH; Skurtveit S; Odsbu I; Chalabianloo F; Lim AG; Johansson KA; Fadnes LT
Subst Abuse Treat Prev Policy; 2020 Jun; 15(1):44. PubMed ID: 32605625
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study.
Carson JM; Dore GJ; Lloyd AR; Grebely J; Byrne M; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Matthews GV; Hajarizadeh B;
Clin Infect Dis; 2022 Nov; 75(10):1809-1819. PubMed ID: 35362522
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
[TBL] [Abstract][Full Text] [Related]
20. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial.
Akiyama MJ; Norton BL; Arnsten JH; Agyemang L; Heo M; Litwin AH
Ann Intern Med; 2019 May; 170(9):594-603. PubMed ID: 30959528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
